- Motley Fool•13 hours ago
Diabetes patients could have new treatment options if Merck, Pfizer, Lexicon, Sanofi, and Novo Nordisk succeed with these three promising drugs.
- Investor's Business Daily•2 days ago
Sanofi makes sense as an acquirer for Flexion Therapeutics, an analyst said Friday, but Flexion investors were dubious.
- Zacks•3 days ago
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||82.42 - 83.11|
|52 Week Range||62.50 - 83.86|
|PE Ratio (TTM)||22.82|
|Dividend & Yield||3.35 (3.75%)|
|1y Target Est||N/A|